CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly Based on Nonparametric Population Pharmacokinetic Modeling and Simulations
Journal Title: International Journal of Clinical Pharmacology & Toxicology(IJCPT) - Year 2017, Vol 6, Issue 1
Abstract
Objective: The primary aim of this article is to test the hypothesis that nonparametric pharmacometric modeling will accurately identify CYP2B6 genotype subgroups based on data from a study that reported results based on parametric pharmacokinetics (PK). Methods: Propofol concentration-time data were originally reported in the Kansaku et al., 2011 publication. Nonparametric Nonlinear Mixed Effects Modeling (NLME) was conducted using the PMETRICS R package while population pharmacokinetic model parameters were estimated using a FORTRAN compiler. Finally, model-based dosing simulations were conducted in the MATLAB Simbiology. Results: A total of 51 patients were included in the final PK analysis. A two-compartment gamma multiplicative error model adequately described the propofol concentration-time data. The individual observed versus predicted R2=0.99 and R-squared=0.93 for the population model predictions. Neither the UGT1A9 nor the CYP2B6 G516T gene variants resulted in statistically significant PK parameter differences while the CYP2B6 A785G gene variants resulted in statistically significant differences for the elimination rate. Model-based dosing-simulations comparing patients with the CYP2B6 AA & AG genotypes to both GG genotypes and patients from a multicenter trial suggest a 50% decrease in propofol infusion dose, to 25mg/ kg/min, be made to result in approximately equivalent drug exposures. Conclusion: Based on the pharmacometric modeling and simulation, if no dosage adjustments are made for the elderly CYP2B6 AA and AG genotypes, a 250% higher propofol blood exposure will be evident within 1-hour from the start of the infusion. Thus, based on the pharmacokinetic model, genotyping elderly patients for the CYP2B6 AA and AG gene variants will decrease the total propofol blood exposure during anesthesia and sedation when an infusion dose adjustment is made to 25mg/kg/min.
Authors and Affiliations
Andy R. Eugene
Keywords
Related Articles
- EP ID EP324145
- DOI 10.19070/2167-910X-1700041
- Views 54
- Downloads 0
Tragedies in Clinical Trials - A History Wrapped Up
Today foremost emphasis is being given to the protection of patient’s safety and ethics during the conduct of clinical trials. Serious considerations by regulatory authorities are taken to safeguard the patient’s right,...
Relationship of Drug-Drug Interactions with Hospital Diagnoses Associated to Adverse Drug Reactions: a Retrospective Study of Billing Data in Austria
Purpose: The objective of this study was to identify hospitalisations in Austria caused by adverse drug reactions (ADR) and to analyse preceding medication for the risk of drug-drug interactions (DDI) based on healthcare...
VKORC1 (-1639) Polymorphisms do not Affect Long-Term Stability of Anticoagulation with Warfarin
The extent of INR fall following vitamin K supplementation to patients on warfarin is related to VKORC1-1639G>A genotype, with those carrying the GG genotype demonstrating a significantly larger fall in INR compared to t...
Efficacy of Montelukast and Ranitidine as an Add on Therapy for Chronic Urticaria
Background: Chronic urticaria is a highly distressing disease affecting a person’s quality of life. In most cases, monotherapy fails. Hence, combinations of antihistamines with montelukast, H2 blockers, ciclosporin, daps...
Evaluation of the Cytotoxic Effects of Combined Application of Methotrexate and Statins on Green Monkey Kidney Cells
Lipid disorders that lead to cardiovascular diseases are also common with oncology patients. Therefore, this group of patients is exposed to the risk of interaction between the cytostatic drugs applied and statins. Metho...